Scarica l'app Stockscreener
15.40
6.28%
0.91
Precedente Chiudi:
$14.49
Aprire:
$14
Volume 24 ore:
1,527
Relative Volume:
0.29
Capitalizzazione di mercato:
$36.72M
Reddito:
$5.02M
Utile/perdita netta:
$-18.31M
Rapporto P/E:
-3.3996
EPS:
-4.53
Flusso di cassa netto:
$-23.40M
1 W Prestazione:
+5.35%
1M Prestazione:
-9.47%
6M Prestazione:
-27.36%
1 anno Prestazione:
+16.84%
Intervallo 1D:
$14.00
$14.03
Intervallo di 1 settimana:
$14.00
$15.68
Portata 52W:
$12.58
$26.99
Vtv Therapeutics Inc Stock (VTVT) Company Profile
Nome
Vtv Therapeutics Inc
Settore
Industria
Telefono
336-841-0300
Indirizzo
3980 PREMIER DR, HIGH POINT, NC
Confronta VTVT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
14.03 | 40.50M | 5.02M | -18.31M | -23.40M | -4.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.59 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.96 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
433.31 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
645.35 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
301.83 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-05-30 | Iniziato | H.C. Wainwright | Buy |
| 2018-04-10 | Downgrade | Stifel | Buy → Hold |
| 2018-03-08 | Iniziato | ROTH Capital | Buy |
| 2018-02-08 | Iniziato | Northland Capital | Outperform |
| 2016-09-26 | Iniziato | H.C. Wainwright | Buy |
| 2015-09-04 | Iniziato | Canaccord Genuity | Buy |
| 2015-08-24 | Iniziato | Piper Jaffray | Overweight |
| 2015-08-24 | Iniziato | Stifel | Buy |
Mostra tutto
Vtv Therapeutics Inc Borsa (VTVT) Ultime notizie
VTv Therapeutics: Q2 Earnings Snapshot - Connecticut Post
Is vTv Therapeutics Inc. trending in predictive chart models [Quarterly Profit Review]Short-Term Trading Alerts - Newser
What earnings revisions data tells us about vTv Therapeutics Inc.Market Risk Summary & Proven Capital Preservation Methods - Newser
How to monitor vTv Therapeutics Inc. with trend dashboardsFree Alpha Driven Watchlist With Alerts - Newser
vTv Therapeutics Inc. Stock Support and Resistance Levels You Should Know [Gold Moves]Safe Entry Zone Tips - Newser
vTv Therapeutics and the Potential of Cadisegliatin in Transforming Type 1 Diabetes Management - AInvest
vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | VTVT Stock News - GuruFocus
vTv Therapeutics Reports Q2 2025 Results, Phase 3 CATT1 Trial Begins - AInvest
vTv Therapeutics Reports First Participant Randomized in Phase 3 CATT1 Trial for Cadisegliatin and Expands Intellectual Property Portfolio - Quiver Quantitative
vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Novel Oral Diabetes Drug Enters Phase 3 Trial: vTv's Potential First-in-Class Treatment Advances - Stock Titan
Is vTv Therapeutics Inc. trending in predictive chart modelsAI Screener Based Stock Summary Report - Newser
Using fundamentals and technicals on vTv Therapeutics Inc.ROI Prediction from Long-Term Holding Plans - Newser
What makes vTv Therapeutics Inc. stock price move sharplySummary of Long-Term Buy Zone Stocks - Newser
vTv Therapeutics VTVT Q2 2025 Earnings Preview Upside Potential on Strategic Partnerships - AInvest
Using data models to predict vTv Therapeutics Inc. stock movementChart Confirmation Setup with ROI Signals - Newser
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin | VTVT Stock News - GuruFocus
What machine learning models say about vTv Therapeutics Inc.Free Low Capital High Return Stock Plans - Newser
vTv Therapeutics Receives Notice of Allowance for Cadisegliatin Patent, Strengthening Protection for Type 1 Diabetes Treatment - Quiver Quantitative
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin - GlobeNewswire
vTv Secures 20-Year Patent Protection for First-in-Class Type 1 Diabetes Drug Cadisegliatin - Stock Titan
Does vTv Therapeutics Inc. fit your quant trading modelFree Growth Focused Entry Plan Suggestions - Newser
Relative strength of vTv Therapeutics Inc. in sector analysisSwing Watchlist With Tight Stop Placement - Newser
What MACD and RSI say about vTv Therapeutics Inc.Short-Term Trade Setup with Forecast Insight - Newser
What’s next for vTv Therapeutics Inc. stock priceShort Term Momentum Based Trading Strategy - Newser
Custom strategy builders for tracking vTv Therapeutics Inc.Free Secure Capital Picks With Upside Potential - Newser
Why vTv Therapeutics Inc. stock attracts strong analyst attentionAI Triggered Buy Zone Forecast System - Newser
vTv Therapeutics Inc. stock retracement – recovery analysisDaily Stock Forecast Powered by AI Tools - Newser
Should I buy vTv Therapeutics Inc. stock before earningsFree Access to Real-Time Trade Insights - Newser
How Resilient Is vTv Therapeutics Inc. Stock During Economic DownturnsFree Trade Setups With AI Powered Filters - Newser
vTv Therapeutics announces first participant randomized in CATT1 Phase 3 trial - TipRanks
vTv Therapeutics begins phase 3 trial for type 1 diabetes oral therapy - Investing.com
vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes - The Manila Times
vTv Therapeutics Announces First Study Participant - GlobeNewswire
Advanced analytics toolkit walkthrough for vTv Therapeutics Inc.Chart Driven Opportunity Scanner with Alerts - Newser
First-Ever Oral Type 1 Diabetes Drug Enters Phase 3 TrialFDA Breakthrough Status Could Transform Treatment - Stock Titan
vTv Therapeutics (VTVT) Expected to Announce Quarterly Earnings on Thursday - Defense World
vTv Therapeutics Inc. stock daily chart insightsFree Community Verified Stock Suggestions - Newser
Moving Average Crossover Confirms Uptrend in vTv Therapeutics Inc.Momentum Based Equity Trading Plans Reviewed - beatles.ru
Vtv Therapeutics Inc Azioni (VTVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.83%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):